SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001420720-24-000018
Filing Date
2024-05-13
Accepted
2024-05-13 16:08:29
Documents
15
Period of Report
2024-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240513x8k.htm   iXBRL 8-K 34032
2 EX-99.1 ibio-20240513xex99d1.htm EX-99.1 17583
  Complete submission text file 0001420720-24-000018.txt   178993

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20240513.xsd EX-101.SCH 4159
4 EX-101.DEF ibio-20240513_def.xml EX-101.DEF 3258
5 EX-101.LAB ibio-20240513_lab.xml EX-101.LAB 13975
6 EX-101.PRE ibio-20240513_pre.xml EX-101.PRE 10318
18 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240513x8k_htm.xml XML 4644
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 24939079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)